Stocks of Eli Lilly and Company (NYSE:LLY) traded higher last session on Wall Street, down -1.90% to $433.99.
According to the data, Eli Lilly and Company (NYSE:LLY) has 25 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. LLY stock price is now 15.09% away from the 50-day moving average and 24.79% away from the 200-day moving average. The market capitalization of the company currently stands at $407.79B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
A total of 5 analysts have issued a hold rating and 17 have given it a buy rating.
.
In other news, LILLY ENDOWMENT INC, 10% Owner sold 194,354 shares of the company’s stock on May 19. The stock was sold for $86,024,241 at an average price of $442.62. Upon completion of the transaction, the 10% Owner now directly owns 101,473,810 shares in the company, valued at $44.04 billion. An SEC document containing details of the transaction can be found on the SEC’s website. On May 15, SVP, Finance, & CAO Zakrowski Donald A sold 600 shares of the business’s stock. A total of $261,174 was realized by selling the stock at an average price of $435.29. This leaves the insider owning 5,978 shares of the company worth $2.59 million. Insiders disposed of 3,882,095 shares of company stock worth roughly $1.68 billion over the past 1 year. A total of 10.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LLY stock. A new stake in Eli Lilly and Company shares was purchased by OFI INVEST ASSET MANAGEMENT during the first quarter worth $23,016,825,000. EDGEWOOD MANAGEMENT LLC invested $920,662,000 in shares of LLY during the first quarter. In the first quarter, ORBIMED ADVISORS LLC acquired a new stake in Eli Lilly and Company valued at approximately $80,722,000. SUMMIT WEALTH GROUP, LLC acquired a new stake in LLY for approximately $60,213,000. SOFINNOVA INVESTMENTS, INC. purchased a new stake in LLY valued at around $59,500,000 in the second quarter. In total, there are 3,352 active investors with 84.80% ownership of the company’s stock.
Monday’s opening bell rang with an opening price of $444.31 for Eli Lilly and Company (NYSE: LLY). During the past 12 months, Eli Lilly and Company has had a low of $283.11 and a high of $447.51. As of last week, the company has a debt-to-equity ratio of 1.69, a current ratio of 1.30, and a quick ratio of 1.00. According to the stock market information, the enterprise value for the company is $390.99B, which is based on a 68.90 price-to-earnings ratio, a 2.83 price-to-earnings-growth ratio, and a beta of 0.35. The fifty day moving average price for LLY is $379.46 and a two-hundred day moving average price translates $348.41 for the stock.
The latest earnings results from Eli Lilly and Company (NYSE: LLY) was released for Mar, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.62, missing analysts’ expectations of $1.73 by -0.11. This compares to $2.10 EPS in the same period last year. The net profit margin was 20.50% and return on equity was 56.20% for LLY. The company reported revenue of $6.96 billion for the quarter, compared to $7.81 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -10.88 percent. For the current quarter, analysts expect LLY to generate $7.53B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 06/09/2023. Investors who held shares on 05/15/2023 were paid a $1.13 dividend. On an annualized basis, this represents a $4.52 dividend and a 1.04% percent yield. There was an ex-dividend date of 05/12/2023 for this dividend. In terms of dividend payout ratio, LLY is presently at 64.50%.
Eli Lilly and Company(LLY) Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
